Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 30];9(6):s602. Available from: https://skin.dermsquared.com/skin/article/view/3885